Evaluation of Toluidine Blue-Mediated Photodynamic Therapy for Experimental Bacterial Keratitis in Rabbits.
bacterial keratitis
photodynamic therapy
rabbit
red light
toluidine blue O (TBO)
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
12 02 2020
12 02 2020
Historique:
entrez:
28
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
The objective of this study was to evaluate the effect of toluidine blue-mediated photodynamic therapy on experimental bacterial keratitis in rabbits. Bacterial keratitis was induced in rabbits by the injection of 200 μl Conjunctival injection and surface area of the corneal ulcer in the TBOR group and the TBOR + LEV group showed significant improvement from baseline after 7 days of treatment. Compared to baseline, the depth of corneal infiltration was decreased at day 14 in the TBOR and TBOR + LEV groups. Microscopic analysis of the TBOR and TBOR + LEV groups showed that the structure of each layer was intact, and there were no inflammatory cells in the corneal stroma. Additionally, IL-1β and TNF-α were highly expressed in the LEV and control groups but were lower in the TBOR and TBOR + LEV groups. Under transmission electron microscopy, the corneas in the TBOR and TBOR + LEV groups were intact, whereas in the LEV and control groups, double-walled structures corresponding to TBOR demonstrated in vivo antibacterial efficacy against This study found in vivo antibacterial efficacy of toluidine blue-mediated photodynamic therapy on rabbit experimental bacterial keratitis, thus providing an additional new option for clinical treatment of bacterial keratitis.
Identifiants
pubmed: 32714639
doi: 10.1167/tvst.9.3.13
pii: TVST-19-1676
pmc: PMC7351589
doi:
Substances chimiques
Tolonium Chloride
15XUH0X66N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
13Informations de copyright
Copyright 2020 The Authors.
Déclaration de conflit d'intérêts
Disclosure: G. Su, None; Z. Wei, None; L. Wang, None; J. Shen, None; C. Baudouin, None; A. Labbé, None; Q. Liang, None
Références
Curr Eye Res. 2006 Mar;31(3):215-24
pubmed: 16531278
Lancet Infect Dis. 2018 Sep;18(9):939-940
pubmed: 30152350
Am J Ophthalmol. 2011 Oct;152(4):567-574.e3
pubmed: 21652021
Euro Surveill. 2015 May 28;20(21):
pubmed: 26062562
JAMA Ophthalmol. 2013 Mar;131(3):310-3
pubmed: 23307105
J Cataract Refract Surg. 2003 Sep;29(9):1780-5
pubmed: 14522301
Transl Vis Sci Technol. 2019 Jun 21;8(3):45
pubmed: 31259090
Antimicrob Agents Chemother. 2008 Jan;52(1):299-305
pubmed: 17967908
Ophthalmology. 2012 Jul;119(7):1320-7
pubmed: 22503230
Curr Microbiol. 2002 Aug;45(2):118-22
pubmed: 12070690
Mol Med Rep. 2017 Apr;15(4):1816-1822
pubmed: 28259957
Invest Ophthalmol Vis Sci. 2011 Jul 18;52(8):5339-46
pubmed: 21613368
Arch Ophthalmol. 2010 Aug;128(8):1022-8
pubmed: 20697003
Cornea. 2004 Jul;23(5):503-7
pubmed: 15220736
Photomed Laser Surg. 2009 Apr;27(2):221-6
pubmed: 19196103
J Antimicrob Chemother. 1998 Jul;42(1):13-28
pubmed: 9700525
FEMS Microbiol Lett. 1998 Mar 15;160(2):177-81
pubmed: 9532735
Eur J Oral Sci. 2006 Feb;114(1):64-9
pubmed: 16460343
Clin Exp Ophthalmol. 2014 Apr;42(3):249-53
pubmed: 23844585
J Environ Pathol Toxicol Oncol. 2006;25(1-2):505-19
pubmed: 16566738
Biochim Biophys Acta. 2007 Sep;1776(1):86-107
pubmed: 17693025
Lasers Med Sci. 2009 Jan;24(1):109-12
pubmed: 18157564
Agents Actions Suppl. 1991;35:69-76
pubmed: 1781423
MMWR Morb Mortal Wkly Rep. 2014 Nov 14;63(45):1027-30
pubmed: 25393221
Am J Ophthalmol. 2016 Jun;166:194-202
pubmed: 27016125
J Antimicrob Chemother. 2007 Jun;59(6):1237-46
pubmed: 17218448
PLoS One. 2014 Dec 01;9(12):e113843
pubmed: 25438169
PLoS One. 2015 Oct 15;10(10):e0140720
pubmed: 26469348
Cutan Ocul Toxicol. 2014 Jun;33(2):138-44
pubmed: 23859535
J Antimicrob Chemother. 1999 Dec;44(6):823-5
pubmed: 10590285
Curr Eye Res. 2004 Jul;29(1):35-40
pubmed: 15370365